Research & Development HMS Daring Prepares for Nine-Month Deployment (UK) View post tag: prepares View post tag: Defence HMS Daring, one of the Royal Navy’s new-generation Type 45 destroyers, is gearing up for a wide-ranging deployment which takes her to the Far East – and beyond.The air defence warship will demonstrate the Navy’s global reach during the nine-month deployment which includes contributing to maritime security in the Asia Pacific, conducting science and technology trials in the Pacific and representing the UK in Exercise Bersama Lima – part of the Five Power Defence Arrangement annual programme of exercises in the region.The deployment will also allow Daring and her 190 crew to represent the UK at high-profile celebrations to mark the 100th anniversary of the Royal Australian Navy.A series of port visits is also lined up for Daring to conduct regional Defence Engagement.Her Commanding Officer, Commander Angus Essenhigh, said:“This exciting deployment will do much to build on existing alliances, establish and strengthen new relationships and contribute to maritime security in the Asia Pacific – a region in which Britain has historic trade and security links.“We will also remain ready to react to contingent operations should they arise.”HMS Daring will leave her home port of Portsmouth on May 27.[mappress]Press Release, May 16, 2013 View post tag: Naval May 16, 2013 Back to overview,Home naval-today HMS Daring Prepares for Nine-Month Deployment (UK) View post tag: Daring View post tag: europe View post tag: Navy View post tag: UK Share this article View post tag: News by topic View post tag: HMS View post tag: Defense View post tag: Nine-Month View post tag: Deployment
Rachel Fraser and Sarah Karacs investigate Teddy Hall guests and discover that tensions break out as worlds collide.
Swiss-based baker Aryzta has unveiled two acquisitions that it hopes will strengthen its market position in Europe and the US.The firm, which produces bread and pastries under brands including Cuisine de France and Delice de France, now owns Fresh Start Bakeries, a global supplier of speciality bakery products, and Great Kitchens, a supplier of pizzas and appetisers with a focus on the deli segment in North America. It follows the announcement that a decline in Aryzta’s like-for-like sales was decelerating in the third quarter; revenues fell by 4.6% to E822.9m (£679.7m) compared to a fall of 8.6% for the nine-month period to April 2010.Aryzta said this decline in revenue was still most evident in Ireland and the UK, where economic conditions remained challenging. The company added that the support provided to customers within c-stores, to reposition their foodservice value proposition through freshly and consistently prepared convenience offerings, was helping to drive footfall. CEO Owen Killian added: “From a business perspective, we will operate with a greater geographic footprint and with much better channel access to consumers. These acquisitions double our manufactured volumes, with an additional 30 production locations in nine countries.”
IndianaLocalNews By Brooklyne Beatty – August 11, 2020 0 362 WhatsApp Facebook Twitter Previous articleThree arrested on several charges after LaGrange County home inspectionNext articleThreats made against fan who posted pics of packed house at Indianapolis Speedrome Brooklyne Beatty Pinterest Google+ TAGScoronaviruscourtCOVID-19Elkhart CountyIndianajurytrials (“My Trusty Gavel” by Brian Turner, CC BY 2.0) Jury trials have resumed in Elkhart County Court.Trials and in-person hearings were suspended in mid-March in order to help slow the spread of COVID-19, but Elkhart County judges believe it’s important to resume regular court proceedings.Several measures have been put in place to keep members of the public safe when they are summoned for jury duty, including:• All visitors will have their temperature checked at the door and be asked screening questions about COVID-19 exposure and travel.• Hand sanitizer is available throughout the courthouse.• Decals have been placed on the ground as a visual guide for social distancing.• Seating in courtrooms and jury rooms has been spaced out to allow at least six feet ofdistance between visitors.• Defendants will continue to appear via videostream from the jail for criminal trials.• A secure filing box is available at the entrance so visitors no longer need to visit the Clerk’s Office to file legal documents.The public is still not permitted into the gallery for trials, but can view a livestream of all court proceedings at public.courts.in.gov.For more information, visit elkhartcountycourts.com. Facebook Twitter Google+ Jury trials resume in Elkhart County Court WhatsApp Pinterest
Earlier this week, Metallica announced that they had to postpone their upcoming performance in Denmark due to singer James Hettfield‘s illness, which affects his throat. This news brought questions regarding their performance at The Grammys on Sunday night. However, just in case Hettfield isn’t back to 100%, they’ve recruited some help for their vocal duties–recent Super Bowl LI Halftime Show star Lady Gaga While Metallica and Lady Gaga sound like a strange pairing, the choice makes more sense than you may think. Some of Gaga’s earliest singing gigs were with a Led Zeppelin tribute band (when she still went by her given name, Stefani Germanotta). Gaga recently got the Led out on Howard Stern, impressively howling a few lines from “Black Dog” and speaking about how to train your voice to withstand the wear of such vocal parts. If her searing wail in the video below is any indication, Lady Gaga will fit right in with Metallica for the televised performance.You can catch Metallica with Lady Gaga, as well as a slew of other star-studded collaborations (like Daft Punk with The Weeknd and A Tribe Called Quest with Anderson .Paak) on Sunday night at 8pm Eastern on CBS.[h/t – Consequence of Sound]
P.S. Run and tell this! Hairspray Live!’s Ephraim Sykes captured the adorable Shahadi Wright Joseph throwing down a rap snippet from “Satisfied.” Watch the pint-sized Schuyler Sister below and be sure to catch the two playing siblings in the NBC broadcast on December 7. Jesus Christ Superstar Makes a Divine ReturnFresh off of winning the Evening Standard Award for Best Musical, it has been announced that the Regent’s Park Open Air Theatre production of Jesus Christ Superstar will make a comeback. The Andrew Lloyd Webber musical will return to the outdoor venue from August 11, 2017 through September 16.Lee Mack to Make West End Debut in The Miser Comedian Lee Mack has joined the previously announced Griff Rhys Jones in Molière’s classic comedy The Miser. Newly adapted by Sean Foley and Phil Porter, the West End production is set to start previews on March 1, 2017, officially opening on March 13 at London’s Garrick Theatre. The limited engagement will end on June 10.Golnesa “G.G.” Gharachedaghi Joins Sex TipsAnother Bravo star is headed to the lucky 777 Theatre! Shahs of Sunset’s Golnesa “G.G.” Gharachedaghi (a.k.a. The Persian Princess) will make her stage debut as Robyn in Sex Tips for Straight Women from a Gay Man from December 3 through December 10. During her time in the production, a portion of the play’s proceeds will benefit her charity Little Warriors, which supports children suffering from a variety of autoimmune diseases.Broadway Isn’t Ready to Make NiceWe know how the Broadway community feels about the results of the presidential election. Last week, a group of powerful young women in the theater community, including A Bronx Tale star (and Broadway.com vlogger) Ariana DeBose, The Color Purple’s Patrice Covington and Spring Awakening alum Kathryn Gallagher, gathered together to raise their voices in song in Central Park. Along with Broadway alums Ashley Park, XiaoChuan Xie, Elisabeth Evans and UptownWorks NYC co-creator Mandie Black, the group performed The Dixie Chicks’ “Not Ready to Make Nice.” Take a look at the video below, which was shot by Broadway.com’s Photo Director Caitlin McNaney and Social Media Manager Caitlyn Gallip. Santino Fontana in ‘Crazy Ex-Girlfriend’ Here’s a quick roundup of stories you may have missed today. Spoiler Alert: Santino Fontana Exits Crazy Ex-GirlfriendWe don’t want to settle for this! Tony nominee and Broadway.com Audience Choice Award winner Santino Fontana has departed the CW’s instant cult fave Crazy Ex-Girlfriend. In the most recent season two episode, his character Greg finally headed off to school to take care of himself and his alcohol addiction. We can’t wait to see what Fontana’s got in store for us next (we’re hoping a guest visit to West Covina now and then). Try not to tear up watching his swan song below, and catch the hilarious show on Fridays at 9PM/8PM Central on The CW. View Comments
By Geraldine Cook/Diálogo February 01, 2017 El Salvador has intensified its fight against the country’s criminal organizations, especially gangs. New government regulations and the participation of the Armed Forces are part of the strategies to eliminate the illegal structures of criminal organizations.Mara Salvatrucha and Barrio 18 are two of the main Salvadoran gangs involved in, among other criminal acts, drug trafficking, arms smuggling, human trafficking, extortion, and kidnapping. According to a report from the Central Reserve Bank of El Salvador published in April 2016, the violence generated by gangs cost the nation $4 million.The financial cost and national and regional security concerns caused by gangs worry Colonel Salvador Ernesto Hernández Vega, general Chief of Staff of the Salvadoran Air Force. That is why since assuming office in December 2015, he has supported his country’s Armed Forces role in helping to keep the peace internally and to defend the sovereignty and integrity of domestic airspace. Combating gangs in his country and throughout Central America has become one of his fundamental priorities.Col. Hernández spoke with Diálogo during the Central American Air Chiefs Conference, held December 12 and 13, 2016 at the Davis-Monthan Air Base in Tucson, Arizona.Diálogo: What is the importance of El Salvador’s presence at the Central American Air Chiefs Conference?Colonel Ernesto Hernández Vega: Participation is important to me because one can meet and interact with leaders from the region’s air forces. I think that it’s quite important. If we are seeking integration in the region and collaboration amongst ourselves, then what could be better than meeting each other and being able to exchange ideas and experiences and, why not, needs and problems? All of this enriches the region and gives us tools to be able to interact and face problems or solutions jointly.Diálogo: What is El Salvador’s goal for its participation in this conference?Col. Hernández: We want to collaborate to prevent transnational crimes like smuggling and the illicit trafficking of drugs through the Central American region. One of our objectives is this: for them to stop using our maritime, land, or air territory for this type of illicit activity. Likewise, it is a good opportunity for us to exchange ideas, propose solutions, or listen to solutions that could benefit the region and El Salvador itself.Diálogo: Which are the most important security issues facing El Salvador?Col. Hernández: Currently, the main issue facing El Salvador is gangs. We have a high daily death rate resulting from this blight, followed by drug trafficking, but I don’t think trafficking affects El Salvador as much as consumption does. Our main problem is gangs, which also affect the country’s economy, stability, and security.Diálogo: What agreements/collaboration programs does your country have with the United States and other partner nations in the region to face these kinds of issues?Col. Hernández: Coming here and being able to interact with various participants in the region demonstrates our collaboration with these countries. El Salvador has collaborative programs with Air Forces Southern and U.S. Southern Command. We’ve also had the opportunity to exchange ideas, recommendations, and solutions with the New Hampshire National Guard, which is our partner state [in the State Partnership Program]. Additionally, this meeting involves several members of the System of Cooperation among the American Air Forces (SICOFAA, per its Spanish acronym), which is an excellent program aimed at regional integration, trust-building, cooperation, and finding solutions to regional problems. It is a regional program that is very beneficial and also gives us the opportunity to interact with leaders from the air forces of Central America. In El Salvador and the Dominican Republic, we have the Central American Armed Forces Conference (CFAC, per its Spanish acronym), which is another beneficial tool, another program to face all the current challenges for the regional armed forces and, specifically, the air forces.As countries from the Central American region, I think that, like many other air forces, we have many weaknesses, such as the scarcity of resources, and I am convinced that we can only face and create solutions to these regional problems by integrating as a region.Diálogo: In terms of SICOFAA, as a member country, what do you think is the importance of this type of integrated cooperation system?Col. Hernández: SICOFAA is quite important because it allows the air forces to know each other better, to have more trust and greater cooperation among air forces. SICOFAA facilitates cooperation, consulting, and the resolution of problems through the kinds of close relationships that we have forged as members.Diálogo: As head of the Salvadoran Air Force, what is your biggest challenge?Col. Hernández: Our fundamental challenge, just like any other air force in the region or the world, is resources. Maintaining and developing an air force anywhere, regardless of what air assets you have, is expensive. So one of the challenges is maintaining an air force that is versatile, competent, useful to the region, and also has personnel that is suitable and appropriately trained to face the challenges that every air force has.Diálogo: Colonel Hernández, would you like to add anything else for readers in the region?Col. Hernández: First, I would like to thank Air Forces Southern for this invitation, and, second, I would like to invite all the air force members who attended [the Central American Air Chiefs Conference] to join forces with each other because integration is the only tool that will give us answers to the needs and issues we have as the Central American region.
Oct 17, 2006 (CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.The vaccine induced an immune response not only against the targeted H5N1 strain, but against other strains as well, according to Baxter. The company announced results of the phase I/II trial Oct 4 but had not released study data until Oct 11, at the World Vaccine Congress in Lyon, France.”This is the first clinical demonstration that a candidate H5N1 vaccine can induce antibodies that neutralize widely divergent strains of H5N1,” said Hartmut Ehrlich, MD, vice president for global research and development, in an Oct 4 Baxter news release. He added that the data “suggest that the vaccine may provide wider protection for a larger number of people before and during a pandemic.”The vaccine was produced using Baxter’s vero cell–based technology and dead whole viruses of wild-type H5N1 avian influenza strain A/Vietnam/1203/2004.Cell-based vaccines are grown in mammalian cells (often from kidneys) instead of chicken eggs and in theory could help meet “surge capacity” needs because the cells can be frozen for stockpiling. The method also can shave about a month off the production time for flu vaccines, which is normally about 6 months. But cell-based flu vaccines face practical hurdles, as discussed below.The cell-based vaccine was administered to 270 healthy adults aged 18 to 45 in Austria and Singapore. Groups of 44 to 48 volunteers received either 3.75, 7.5, 15, or 30 micrograms (mcg) of the vaccine with an aluminum oxide adjuvant, a substance that stimulates immune response. Two other groups of 45 each received 7.5 or 15 mcg of vaccine without an adjuvant. All volunteers were vaccinated on the first day of the trial and again 21 days later.Three weeks after the second injection, testing of serum samples showed that 15 of 23 (65%) volunteers in the 3.75-mcg group had a strong antibody response to the vaccine virus (microneutralization titer 1:20 or higher). In comparison, 15 in 20 (75%) of the adjuvanted 7.5-mcg group and 22 of 27 (82%) of the nonadjuvanted 7.5-mcg group showed a strong antibody response.The vaccine also showed evidence of cross-protection against other H5N1 strains. Microneutralization testing for antibody response to a 1997 Hong Kong strain showed a 71% (12 of 17) rate of response in the 3.75-mcg group, compared with an 81% (13 of 16) and a 96% (21 of 22) response in the adjuvanted and nonadjuvanted 7.5-mcg groups, respectively.For a 2005 H5N1 strain from Indonesia, the rates of antibody response were 35% (6 of 17), 63% (10 of 16), and 68% (15 of 22), respectively.Commenting on the diverse makeup of these nontargeted H5N1 viruses, Ehrlich told CIDRAP News via e-mail, “They are strains that are substantially different from Vietnam 1203. One is the same clade [family] but emerged 7 years earlier; the other one is a different clade. [This is] in contrast to many other strains—for example, Vietnam 1194—which are very similar to Vietnam 1203 and are expected to therefore induce cross-neutralization . . . and were indeed protective in our animal studies.”Ehrlich, who presented the data in Lyon, said the serum samples from the volunteers who received 15 or 30 mcg of the vaccine had not yet been analyzed. Final results of the study will be available by the end of the year, according to the Baxter news release.The rate of adverse events, released this week, demonstrated the apparent safety of the vaccine. After two injections, 3% of patients (6 of 201) had fever, 6.0% (12 of 201) experienced malaise, and 3.5% (7 of 201) reported shivering, the company said.Commenting on the implications of the findings, infectious-disease expert Michael T. Osterholm, PhD, MPH, said Baxter’s vaccine—like other H5N1 vaccines in development—is a long way from offering an early solution to the threat of a flu pandemic. Osterholm is director of the University of Minnesota Center for Infectious Disease Research and Policy, publisher of the CIDRAP Web site.Aside from the problem that it will take months to develop a specific vaccine once a pandemic strain of flu emerges, the Food and Drug Administration has not yet approved any cell-culture flu vaccine, Osterholm told CIDRAP News. “In fact, they’re a long ways from licensure,” he said.In addition, efforts to use a vaccine during a pandemic will encounter a host of practical problems, he added. “We have to think of the whole supply chain. What about syringes? Will they be available when a pandemic hits? What about a whole host of supplies that we’ll need during a pandemic that won’t be available because of our just-in-time infrastructure?”These practical considerations are so crucial that, if all these new vaccines were released today, none of them would make the world a safer place.”Baxter said it plans to begin phase III trials of the vaccine early next year.Baxter is collaborating with DynPort Vaccine Corp. to develop cell-based vaccines. In May, the US Department of Health and Human Services awarded DynPort a $41 million contract for cell-based flu vaccine work. The funds came from $3.3 billion that Congress appropriated for pandemic preparedness last December.See also:Baxter news releasehttp://www.rxpharmacy.md/news/baxter_announces_safety_and_immunogenicity_results_from_phase_i_ii_clinical_trial_of_cell_based_candidate_h5n1_pandemic_vaccine.htmlMay 4 CIDRAP News story “US awards $1 billion for cell-based flu vaccines”Jun 27, 2005, CIDRAP News story “Momentum builds for cell-culture flu vaccines”
May 26, 2009 (CIDRAP News) –Two vaccine companies, Sanofi Pasteur and GlaxoSmithKline, recently announced they received their first orders from the US government for a vaccine and adjuvant to protect the country against the novel H1N1 virus.Sanofi, in a statement released yesterday, said the initial order it received from the Department of Health and Human Services (HHS) covers the production of bulk vaccine and related activities and is worth $190 million. On May 22, Glaxo said in a press release that HHS ordered vaccine antigen and the company’s proprietary adjuvant system, AS03. Adjuvants are compounds that enhance a vaccine’s immune response, offering the possibility of stretching antigen supplies.The announcements from the two companies follow a May 22 announcement from HHS that secretary Kathleen Sebelius was directing about $1 billion in existing funds toward clinical studies and commercial production of bulk vaccine antigen and adjuvant.Federal officials have announced plans to support the development of a novel H1N1 vaccine, but have taken pains to explain that the decision to use it would be made separately.The Centers for Disease Control and Prevention (CDC) has said it hopes to wrap up work on a seed strain to send to vaccine makers within the next few weeks. Once companies receive the seed strain, they can develop pilot lots to begin safety, efficacy, and dosage testing.The federal government’s placement of the orders falls under existing contracts that the Biomedical Advanced Research and Development Authority (BARDA) established with the companies in 2004 as part of the nation’s pandemic influenza strategy.Sanofi said it hopes to begin work on a pilot lot in June after the US Food and Drug Administration approves its working seed. The company said clinical trials could begin as early as August, but a timeline for final formulation, filling, and distribution has not been set.Wayne Pisano, Sanofi’s president and chief executive officer, said in the press release that though a number of complex steps need to be taken before a vaccine is available, the company’s experience in developing the prepandemic H5N1 avian influenza vaccine will be helpful. “We look forward to further demonstrating our experience and expertise in vaccine development as we prepare for this new threat from AH1N1,” he said.Production of the new H1N1vaccine for HHS will take place at the company’s recently licensed new production facility in Swiftwater, Pa. As soon as the company finishes production of seasonal influenza vaccine at its second Swiftwater facility, it can produce the novel H1N1 vaccine at both plants. The two plants, when operating at full capacity, can make about 150 million doses of seasonal flu vaccine.Meanwhile, Glaxo said it expects to fill HHS’ adjuvant order within the next few months and hopes to produce the first antigen doses 4 to 6 months after receiving the novel H1N1seed strain. The company said its proprietary adjuvant, already approved as a component of the H5N1 vaccine in Europe and some Asian countries, is the subject of 15 additional clinical trials, including one involving a seasonal flu vaccine.Both Sanofi and Glaxo said they are in ongoing discussions with other countries about producing novel flu vaccine for national stockpiles.See also:May 25 Sanofipress releaseMay 22 Glaxopress releaseMay 22 HHS press releaseMay 6 CIDRAP News story “FDA approves new vaccine facility”
EnBW has installed 44 of the 87 Siemens Gamesa wind turbines on the Hohe See and Albatros offshore wind farms in the German North Sea.Fred. Olsen Windcarrier’s installation vessels Brave Tern and Blue Tern load the components for four wind turbines at a time at the port of Esbjerg in Denmark and attach them offshore to foundations already installed in the seabed.The first turbine was installed at the site some 95 kilometres north of Borkum and 100 kilometres northwest of Helgoland in early April.The total of 87 Siemens Gamesa 7MW wind turbines with 609MW of installed output are due to be connected to the grid by the end of 2019.The project is being coordinated by the offshore branch of EnBW in Hamburg. The Canadian energy infrastructure company Enbridge Inc. holds 49.9 percent of the shares in the 71-turbine Hohe See and the neighbouring 16-turbine Albatros. EnBW has retained the remaining 50.1 percent in both projects.Photos: Fred. Olsen Windcarrier AS/Tony Cato